TY - JOUR
T1 - Twenty-Year Survival in Glioblastoma
T2 - A Case Report and Molecular Profile
AU - Sperduto, Christina Maria
AU - Chakravarti, Arnab
AU - Aldape, Ken
AU - Burger, Peter
AU - Papermaster, Gail Bender
AU - Sperduto, Paul
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009/11/15
Y1 - 2009/11/15
N2 - Background: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. Method: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. Results: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. Conclusion: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.
AB - Background: The prognosis for patients with glioblastoma (GB) remains grim. Historically, the median survival has been 6 to 9 months. Recent research has improved the outcome slightly. A computer search of the literature reveals few long-term survivors. Method: Presented here is a case report of a 20-year survivor of GB, with pathologic review to confirm the diagnosis. A battery of molecular studies was performed to develop a molecular profile of this unique patient. Results: The results of the molecular genetic testing for this most unusual patient were as follows: (1) methylguanine methyl transferase (MGMT) was methylated, (2) p53 positive, (3) PTEN tumor suppressor gene positive, (4) protein kinase AKT (pAKT) negative, and (5) epidermal growth factor receptor negative. Conclusion: To our knowledge, this is the longest survival of any patient in the literature whose initial diagnosis was GB. Triple-positive GBM patients (MGMT methylated, PTEN, and p53 positive) are uncommon but may be associated with a better prognosis. Further research is needed to confirm whether this molecular profile is prognostic of prolonged survival. Molecular genetics will determine future treatment and prognosis in GB.
KW - Glioblastoma
KW - Molecular Profile
KW - Outcomes
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=70449730262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70449730262&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2008.12.054
DO - 10.1016/j.ijrobp.2008.12.054
M3 - Article
C2 - 19327897
AN - SCOPUS:70449730262
SN - 0360-3016
VL - 75
SP - 1162
EP - 1165
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -